BioCentury
ARTICLE | Strategy

Caprion HUStles to the clinic

June 14, 2004 7:00 AM UTC

For target discovery companies like Caprion Pharmaceuticals Inc., forward integration involves procurement not only of product development capabilities but also of a product discovery platform. Last week's deal with Sunol Molecular Corp. gives Caprion a bit of both. It is now up to Caprion to develop programs around those footholds.

According to President and CEO Lloyd Segal, Caprion has promised since it first raised significant capital in 2000 that it would integrate forward as soon as it had a critical mass of targets. The company has used its CellCarta platform to identify solid tumor antigens amenable to targeting with monoclonal antibodies, and expects to have targets by year end for lung, colon and prostate cancers...